Drug Profile
Trenonacog alfa - Medexus Pharmaceuticals
Alternative Names: APVO-101; IB-1001; IXINITY; Nonacog-alfa biosimilar - Inspiration; Recombinant factor IX biosimilar - InspirationLatest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Inspiration Biopharmaceuticals
- Developer Aptevo Therapeutics; Cangene Corporation; Medexus Pharmaceuticals
- Class Antihaemorrhagics; Blood coagulation factors; Peptides; Recombinant proteins
- Mechanism of Action Factor IX replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Haemophilia B
Most Recent Events
- 08 Mar 2024 The US FDA accepts for review the Pediatric label expansion application for Trenonacog alfa
- 28 Dec 2022 No development reported - Clinical-Phase-Unknown for Haemophilia B (In children, In infants, In neonates) in USA (IV)
- 13 Aug 2021 Medexus Pharmaceuticals completes enrolment in a phase IV label expansion clinical trial in Haemophilia B (In children, In infants, In neonates)